[go: up one dir, main page]

SG11202006813TA - Fasoracetam crystalline forms - Google Patents

Fasoracetam crystalline forms

Info

Publication number
SG11202006813TA
SG11202006813TA SG11202006813TA SG11202006813TA SG11202006813TA SG 11202006813T A SG11202006813T A SG 11202006813TA SG 11202006813T A SG11202006813T A SG 11202006813TA SG 11202006813T A SG11202006813T A SG 11202006813TA SG 11202006813T A SG11202006813T A SG 11202006813TA
Authority
SG
Singapore
Prior art keywords
fasoracetam
crystalline forms
crystalline
forms
fasoracetam crystalline
Prior art date
Application number
SG11202006813TA
Inventor
Tom Leyssens
Bram Harmsen
Original Assignee
Childrens Hospital Philadelphia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Childrens Hospital Philadelphia filed Critical Childrens Hospital Philadelphia
Publication of SG11202006813TA publication Critical patent/SG11202006813TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D207/282-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
SG11202006813TA 2018-01-18 2019-01-17 Fasoracetam crystalline forms SG11202006813TA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862619031P 2018-01-18 2018-01-18
US201862668108P 2018-05-07 2018-05-07
US201862683419P 2018-06-11 2018-06-11
PCT/US2019/014027 WO2019143829A1 (en) 2018-01-18 2019-01-17 Fasoracetam crystalline forms

Publications (1)

Publication Number Publication Date
SG11202006813TA true SG11202006813TA (en) 2020-08-28

Family

ID=67301590

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006813TA SG11202006813TA (en) 2018-01-18 2019-01-17 Fasoracetam crystalline forms

Country Status (12)

Country Link
US (2) US11535604B2 (en)
EP (1) EP3740587A4 (en)
JP (1) JP2021511336A (en)
KR (1) KR20200135771A (en)
CN (1) CN111936463A (en)
AU (1) AU2019209870B2 (en)
BR (1) BR112020014675A2 (en)
CA (1) CA3088970A1 (en)
IL (1) IL276108A (en)
SG (1) SG11202006813TA (en)
WO (1) WO2019143829A1 (en)
ZA (1) ZA202004942B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2597100A1 (en) * 1986-01-21 1987-10-16 Nippon Shinyaku Co Ltd PYROGLUTAMIDE DERIVATIVES
US5652249A (en) * 1993-07-28 1997-07-29 Nippon Shinyaku Co., Inc. Method of treating depression
US11219617B2 (en) * 2014-05-30 2022-01-11 The Children's Hospital Of Philadelphia Methods of diagnosing and treating autism
DK3347014T3 (en) 2015-09-08 2021-12-06 Childrens Hospital Philadelphia Methods for diagnosing and treating Tourette's syndrome
EP3509640A1 (en) 2016-09-07 2019-07-17 The Children's Hospital of Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of anorexia nervosa and binge eating disorder
EP3740204A4 (en) * 2018-01-18 2021-10-06 The Children's Hospital Of Philadelphia SOLID FORMS OF FASORACETAM

Also Published As

Publication number Publication date
CN111936463A (en) 2020-11-13
BR112020014675A2 (en) 2021-02-17
US11535604B2 (en) 2022-12-27
ZA202004942B (en) 2023-12-20
WO2019143829A1 (en) 2019-07-25
AU2019209870A1 (en) 2020-09-03
US20230088814A1 (en) 2023-03-23
US20210047288A1 (en) 2021-02-18
JP2021511336A (en) 2021-05-06
US12110284B2 (en) 2024-10-08
EP3740587A4 (en) 2021-10-13
CA3088970A1 (en) 2019-07-25
AU2019209870B2 (en) 2024-06-13
EP3740587A1 (en) 2020-11-25
IL276108A (en) 2020-08-31
KR20200135771A (en) 2020-12-03

Similar Documents

Publication Publication Date Title
IL273730A (en) Crystalline forms
IL276644A (en) Novel crystalline forms
DK3467457T3 (en) Vibrationssensor
DK3759096T3 (en) Cd73-inhibitorer
PT3810587T (en) Substituted alkoxypyridinyl indolsulfonamides
CA185383S (en) Casque
CA185384S (en) Casque
CA185382S (en) Casque
CA185385S (en) Casque
DK3554057T3 (en) Audioheadsetsystem
DK3768830T3 (en) Cancerterapi
DK3613739T3 (en) Integrin-antagonister
DK3753395T3 (en) Indvendigt luftstyringssystem
CA184990S (en) Uroflowmeter
CA184994S (en) Uroflowmeter
DK3633783T3 (en) Universal-powerbank
IL265445A (en) Crystalline forms
DK3674425T3 (en) Stålwire
DK3650069T3 (en) Trakeostomiventil
DK3578923T3 (en) Navigationssystem
DK3570498T3 (en) Adaptivt hvac-styresystem
GB201818028D0 (en) Crystalline materials
GB201816445D0 (en) Crystalline materials
IL276108A (en) Fasoracetam crystalline forms
GB201911797D0 (en) Crystalline forms